In 2025, Dr. Husam Abu Jazar and colleagues at King Hussein Cancer Center published two impactful studies that could shape transplant care moving forward. The first study analyzed outcomes from 51 patients who received haploidentical peripheral blood stem cell transplants with earlier immunosuppression (day 0–1). This approach resulted in 98% neutrophil and 96% platelet engraftment, low rates of severe cytokine-release
syndrome, and a three-year overall survival of 51.8%.
Full study: https://lnkd.in/eggVgpgC
The second study evaluated the use of eltrombopag in 23 patients with poor graft function following allogeneic HCT. The results showed meaningful hematologic recovery and a 65% response rate, confirming the drug’s safety and potential benefit in this setting.
Full study: https://lnkd.in/eZ_iBdvR
These findings reflect KHCC’s continued leadership in advancing care for patients with hematologic malignancies and post-transplant complications.
